Join the club for FREE to access the whole archive and other member benefits. summarises the proceedings of the Buck Institute's Longevity Summit

Another reminder of the amount of research, with multiple approaches, about to go into clinical trials


Key points from article :

Eric Verdin - finding reliable biomarkers of aging

  • need to work across tissues and populations
  • two sexes age differently
  • blood test average as many as 50 different cell types
  • TRIIM trial' considerable epigenetic age reversal could be due to shifts in the population of T cells

Morgan Levine - Altos Labs

  • biomarker of aging should be an independent predictor of morbidity and mortality
  • want minimal variation in test-retest scores - traditional clock readings from the same sample can differ by as much as nine years
  • team have developed a method of denoising existing clocks

Priyanka Joshi -  co-founder of NeuroAge

  • aggregated proteins fail to perform their functions
  • company is working on a large postmortem cohort of about 2000 brains
  • people with biological age younger than their chronological age were less likely to have developed Alzheimer’s

Sergio Ruiz - CEO of

  • presented the company’s latest work on CAR T cell rejuvenation
  • young cells renew the cellular environment
  • focussing on immunology and dermatology for immediate commercialization
  • hopes to begin Phase 1 and 2 clinical trials as early as 2024

Hanadie Yousef - CEO of Juvena Therapeutics

  • has created a proprietary library of secreted proteins with therapeutic potential
  • has 33 hits that can promote rejuvenation of various tissues
  • uses unbiased quantitative proteomics and machine learning

Jennifer Garrison - assistant professor at Buck

  • ovaries age 3.5 times faster than other organs
  • while women on average live longer than men, their healthspan is shorter
  • older age at menopause correlates with life expectancy  - also in their brothers
  • part of the Global Consortium for Reproductive Longevity and Equality (GCRLE)

Spring Behrouz and Andy Lee - founders of Vincere Therapeutics

  • start-up company focused on mitochondrial dysfunction
  • parkin enzyme tags malfunctioning mitochondria for recycling
  • aims to create small molecules that would either aid parkin or block USP30

Marco Quarta - CEO of Rubedo

  • a cell can be triggered into various states of senescence by different stressors
  • employs a proprietary AI-driven platform
  • based on single-cell technologies because bulk samples noisy
  • one of Rubedo’s prodrugs nearly completely eliminated senescent cells with minimum to no damage to healthy cells

Matt Kaeberlein - University of Washington professor

  • Dog Aging Project (DAP) is an open geroscience project
  • more than 41,000 dogs enrolled in the DAP’s longitudinal arm
  • one meal a day is associated with lower risk across a wide range of diseases
  • Test of Rapamycin in Aging Dogs (TRIAD), which is about to begin

Ashley Zehnder - CEO of FaunaBio

  • harnessing the mechanisms that make some species particularly long-lived
  • particular focus on hibernation
  • searching for the genes responsible for these amazing feats of evolution

Eric Morgen - founder of BioAge

  • clinical-stage biotech with a portfolio of therapies that target the molecular causes of aging
  • overarching goal is compression of morbidity
  • uses a cohort of more than 10,000 patients to take longitudinal measurements of agin
  • protein apelin is associated with longevity and muscle strength - candidate drug significantly prevented muscle atrophy

Yvonne Dotson and Stacie Walton - The Diversity Doctor

  • discrimination faced by African-American women in the healthcare system
  • undertreated for pain and are less likely to receive hormone replacement therapy after menopause

Mentioned in this article:

Click on resource name for more details.

Altos Labs

Biotechnology company focused on cellular rejuvenation programming

Ashley Zehnder

Co-founder and CEO at Fauna Bio


Developing a broad pipeline of therapies to extend human healthspan and lifespan

Buck Institute

Independent biomedical research institute focused on aging

Eric Morgen

COO and Co-founder at BioAge Labs

Eric Verdin

CEO & President at Buck Institute for Research on Aging

Fauna Bio

Developing human therapeutics from animal genomics

Hanadie Yousef

Co-founder and CEO of Juvena Therapeutics

Jennifer Garrison

Assistant Professor and Co-Founder & Director of Global Consortium for Reproductive Longevity & Equality at Buck Institute

Juvena Therapeutics

Biopharma discovering novel protein-based therapeutics that promote tissue regeneration

Marco Quarta

Co-Founder CEO at Rubedo Life Sciences

Matt Kaeberlein

Professor at University of Washington and chair of the American Aging Association

Morgan Levine

Founding Principal Investigator at Altos labs, Authored True Age book

NeuroAge Therapeutics

Longevity pharmatech that creates drugs to rejuvenate biological brain aging and treat neurodegenerative disorders

Priyanka Joshi

Co-founder of NeuroAge Therapeutics and Research Fellow at University of California, Berkeley

Rubedo Life Sciences

Extending Health Span and Reverting Age-Related Diseases.

Sergio Ruiz

Chief Operating Officer at Turn Biotechnologies.

Turn Biotechnologies

Focused on restoring cells’ youthful vigor to repair damage caused by the aging process

Vincere Biosciences

Company with mission to develop drugs to halt the progression of Parkinson's disease

Topics mentioned on this page:
Ageing Research summarises the proceedings of the Buck Institute's Longevity Summit